Akari Announces Coversin Data to be Presented at 2018 Complement-Based Drug Development Summit

NEXT STORY
LEARN Behavioral Announces Partnership with Cognoa to Empower Parents and Enable Earlier Diagnosis
PREV STORY
TRACON Pharmaceuticals Presents New Circulating Tumor Cell Data from Ongoing Pivotal Phase 3 TAPPAS Trial of TRC105 and Votrient® in Patients with Angiosarcoma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Axsome Therapeutics Announces AXS-07 Achieves Both Co-Primary Endpoints and Prevents Migraine Pain Progression in the INTERCEPT Phase 3 Trial in the Early Treatment of Migraine

author_avatar
NASDAQ Market News

Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors

author_avatar
NASDAQ Market News

AIT Therapeutics Announces Positive Preliminary Data for the Primary Endpoint of Safety in Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) Patients

No Serious Adverse Events Related to Treatment with Nitric Oxide Reported Compelling Preliminary Data ...

author_avatar
NASDAQ Market News